Therapeutic efficacy of dapagliflozin combined with sacubitril valsartan for heart failure complicated with type 2 diabetes mellitus
10.3969/j.issn.1009-0126.2025.02.012
- VernacularTitle:达格列净联合沙库巴曲缬沙坦对心力衰竭合并2型糖尿病患者的治疗效果研究
- Author:
Linqing WANG
1
;
Yajing ZHANG
;
Jieqian XUE
;
Yunjing SUN
;
Song ZHOU
Author Information
1. 054000 邢台市中心医院心内科二病区
- Publication Type:Journal Article
- Keywords:
heart failure;
diabetes mellitus,type 2;
blood glucose;
ventricular function,left
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2025;27(2):178-182
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic efficacy of combination of dapagliflozin and sacubitril valsartan on patients with heart failure(HF)complicated with type 2 diabetes mellitus(T2DM).Methods A retrospective study was conducted on 160 patients with HF and T2DM admitted to our hospital from November 2020 to November 2022.According to drug treatment,they were classified into sacubitril valsartan group(80 cases)and combined group(dapagliflozin combined with sacubitril valsartan,80 cases).After 3 months of treatment,the differences were compared between the two groups in following aspects:blood glucose fluctuations,left ventricular diastolic function,and vascular endothelial function,and the incidence of adverse events after 1 year of follow-up.Results After 3 months of treatment,serum FPG,2 h-PG and HbAlc levels,and MAGE,LAGE,MODD and SDBG values were significantly lower in the combined group than the sacubitril valsartan group(P＜0.05,P＜0.01).The combined group had obviously higher e'and LVEF values while lower LVMI and BNP levels than the other group(P＜0.05,P＜0.01).After 3 months of treatment,NO and FMD were notably higher[96.18±6.70 ng/L vs 92.34±6.85 ng/L,P=0.000;(8.25±1.16)％vs(7.72±1.28)％,P=0.007],while ET-1(59.72±4.95 ng/L vs 63.90±4.63 ng/L,P=0.000)was remarkably lower in the combined group than the sacubitril valsartan group.There was no statistical significance in the total incidence of adverse events between both groups after 1 year of follow-up(P＞0.05).Conclusion The combination of dapagliflozin and sacubitril valsartan has a significant improvement effect on blood glucose,left ventricular diastolic function and vascular endothelial function in T2DM patients with HF,with good drug safety.
